ArticleJournal of the National Cancer Institute2026
Walking dose associated with lower cancer-related fatigue among patients with breast cancer.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCancer-related fatigue is a debilitating side effect among patients with cancer. Exercise is recommended to manage cancer-related fatigue; however, clinical guidelines lack specificity on modality, intensity, and duration. This study aimed to determine the optimal doses of walking to mitigate cancer-related fatigue.
methodsIn a nationwide, prospective cohort study of patients with stage I-IIIC breast cancer, we assessed walking volume (metabolic equivalent task [MET] hours per week) via Aerobics Center Longitudinal Study Physical Activity measure and cancer-related fatigue via Multidimensional Fatigue Symptom Inventory at prechemotherapy (T1), 1 month postchemotherapy (T2), and 6 months postchemotherapy (T3). A receiver operating characteristic curve analysis identified a cut point for walking volume needed for a clinically meaningful cancer-related fatigue reduction from T1 to T2 (-4.5 points Multidimensional Fatigue Symptom Inventory score). Linear mixed models controlling for age, body mass index, and other modes of moderate-vigorous intensity exercise characterized cancer-related fatigue at each time point.
resultsAmong 577 participants (mean age = 53.4 years; 76% stage I-II), higher walking volume was associated with lower general, emotional, physical, overall cancer-related fatigue, and higher vigor postchemotherapy (T2; all P < .05). Those who walked at least 4.3 MET hours per week, equivalent to walking 88-172 minutes at a low-intensity pace (<2.5 mph) or 43-83 minutes at a moderate-intensity pace (2.6-4.5 mph) at pre, during, and postchemotherapy demonstrated statistically significantly lower cancer-related fatigue at postchemotherapy (T2) compared with those who walked less than 4.3 MET hours per week (P < .05).
conclusionsOur data indicate that higher walking volume was associated with lower cancer-related fatigue, and a minimum walking volume of 88-172 minutes at a low-intensity pace or 43-83 minutes of moderate-intensity pace may attenuate cancer-related fatigue following chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.